Virpax Pharmaceuticals

Virpax Pharmaceuticals is a preclinical-stage biopharmaceutical company dedicated to becoming a global leader in pain management by developing and delivering innovative non-opioid and non-addictive pharmaceuticals through the use of novel drug delivery systems and technologies. Virpax Pharmaceuticals is utilizing advanced technology to develop branded drug candidates for pain management, aiming to improve patients' quality of life. Virpax Pharmaceuticals holds the global exclusive rights to develop, market, and export (among other rights) proprietary generic-like non-steroidal anti-inflammatory topical spray film delivery technology, which can be used for acute musculoskeletal pain ("DSF100" or "EpoladermTM") and chronic knee osteoarthritis ("OSF200"). Virpax Pharmaceuticals also possesses the global exclusive rights to a patented long-acting "local anesthetic" liposome (Hydro) gel technology for postoperative pain management ("LBL100" or "ProbudurTM"). Additionally, Virpax Pharmaceuticals owns the global exclusive rights to molecular encapsulation technology ("MET"), which uses intranasal devices to deliver exogenous enkephalins for treating acute and chronic pain ("NES100") and dysregulated post-traumatic stress responses ("PES200").